Clinical Trial Update: Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluated radiation therapy, plasma exchange, and immunotherapy with pembrolizumab or nivolumab for melanoma. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• OPDIVO (nivolumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Melanoma | EARLY_Phase 1 | Status: COMPLETED